Duchesnay Pharmaceutical Group Expands Global NVP Portfolio
Duchesnay Pharmaceutical Group (DPG) is thrilled to announce a significant milestone in its journey, expanding its treatment portfolio for nausea and vomiting of pregnancy (NVP) to over 40 countries worldwide. This achievement signifies the company's commitment to women's health and its dedication to providing effective treatment options for expectant mothers suffering from NVP, also commonly referred to as 'morning sickness.'
A Tradition of Innovation and Care
At the core of this expansion is DPG's patented combination of doxylamine succinate and pyridoxine hydrochloride, a formulation recognized for its safety and efficacy in treating NVP. Manufactured locally within DPG's advanced facility, this product is available under various trade names, including Xonvea and Bonjesta, demonstrating DPG's versatility in meeting global healthcare requirements.
Long-standing Commitment to Women's Health
Michael Gallo, Vice-President of Regulatory & Medical Affairs, emphasizes the legacy of the portfolio, stating, "This treatment has a 40-year history of safe use among pregnant women to alleviate NVP. The team's efforts have been crucial in recognizing nausea and vomiting during pregnancy as a legitimate medical condition and have led to pivotal advancements in managing this often debilitating experience. By advocating for better treatment options, we aim to create a positive impact on the lives of many women."
Driving Global Access
With regulatory approvals acquired in 13 more countries recently, DPG is eager to continue its global outreach. The company’s success would not have been possible without collaboration from international partners and the unwavering commitment of its teams to address a universal medical need.
Global Partnerships for NVP Solutions
Suzanne Paszkiewicz, Vice-President of Global Partnerships & Business Development at DPG, asserts the importance of their work: "The challenges that NVP presents are faced by women worldwide. Our mission is to ensure that these effective solutions are accessible, and we remain steadfast in our efforts to meet this pressing medical demand globally."
About Duchesnay Pharmaceutical Group
Duchesnay Pharmaceutical Group, headquartered in Blainville, Quebec, is a prominent player in the pharmaceutical industry, focused on women's health and specialty medicine. The Group consists of several companies, including Duchesnay Canada and Duchesnay USA, both dedicated to improving women’s health, as well as companies that address rare diseases and generic medications.
Through innovative research and development, along with strategic alliances, DPG has established itself as a reliable provider of treatments for various medical conditions, particularly in women’s health, urology, and oncology. Moreover, its state-of-the-art manufacturing capabilities empower DPG to export its treatments to over 50 countries, further enhancing healthcare accessibility.
As one of eight Canadian companies selected for the Government of Canada's Global Hypergrowth Project, DPG is poised for significant development with dedicated support to strengthen its presence in the global market.
The commitment to corporate social responsibility drives DPG to engage in charitable initiatives and maintain environmental standards, reflecting the company's core values and dedication to the community.
Frequently Asked Questions
What is the main focus of Duchesnay Pharmaceutical Group?
Duchesnay Pharmaceutical Group primarily focuses on women's health and specializes in treatments for nausea and vomiting of pregnancy.
How many countries has DPG's NVP portfolio expanded to?
DPG has successfully expanded its NVP treatment portfolio to over 40 countries around the world.
What ingredients are in DPG's NVP treatment?
The primary ingredients in DPG's NVP treatment are doxylamine succinate and pyridoxine hydrochloride.
What is the heritage of DPG's NVP treatment?
DPG's NVP treatment has a solid 40-year history of safe usage during pregnancy, addressing the challenges associated with nausea and vomiting.
What initiatives is DPG involved in related to growth?
DPG participates in the Government of Canada's Global Hypergrowth Project, which provides support aimed at accelerating its market growth.
